Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. - Test2 - elhamkhani - TriplyDB

Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.

Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q38208461

about

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.Can donepezil facilitate weaning from mechanical ventilation in difficult to wean patients? An interventional pilot study.Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).Effects of donepezil on liver and kidney functions for the treatment of Alzheimer's disease.circHIPK2-mediated σ-1R promotes endoplasmic reticulum stress in human pulmonary fibroblasts exposed to silica.

P2860

Q33586027-F938E360-3BA2-4324-8618-5E55770721E2 Q35218488-AF87881C-B230-486D-BBE3-849ACFD2B8E3 Q37082335-865D656E-ABFB-456B-9E7C-0D4D445468CC Q37712599-6E2252AD-E0CA-4079-8571-513AB26997B4 Q39415447-99E660EB-A3CE-4B08-8220-38BA4BD88E3F Q41702520-2A39B493-E1DB-4231-96A9-0688746141D0 Q47273416-3E9BA607-0A93-4885-95B9-821D8B2E59B2 Q47295982-30B665B7-2DAF-4F1C-B42A-01F604F47438

P2860

Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q38208461

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetic and pharmacody ...... atment of Alzheimer's disease.

@en

type

label

Pharmacokinetic and pharmacody ...... atment of Alzheimer's disease.

@en

prefLabel

Pharmacokinetic and pharmacody ...... atment of Alzheimer's disease.

@en

P1433

Q38208461-01E75116-946A-4DC6-8899-56558FE36A0A

P1476

Q38208461-90A9A4BD-1104-4CB0-BB81-3F461C076FF7

P2093

Q38208461-6E562CA8-05FE-4F18-8CEA-A8F614DCAC0C

Q38208461-F1DE2F35-9166-4F34-85CE-FBAC9FF45F87

P2860

Q38208461-04C3035D-94B1-4CAF-BD38-EF997A4A7B6B

Q38208461-07A6F94D-EF74-4AE9-87DC-A7874A562A9E

Q38208461-0B5AE23E-0494-49B5-BA8D-09AE7767A5E6

Q38208461-0E334DCD-0A3A-4D36-A0C7-5E08EFC77F6A

Q38208461-0EDEBF34-C4D4-47B1-80F8-C547237E303D

Q38208461-0F450EDF-0246-4F72-A33B-405CE1CFF9C1

Q38208461-13646B53-AE0A-4D6F-8B92-643D8A01A543

Q38208461-1384DED1-A49A-4C66-9438-E8A08A8531E4

Q38208461-174F6B73-D257-47CD-8956-7AC38B787495

Q38208461-1AF221E0-E5DD-4BA9-97D2-9336A4A50412

P304

Q38208461-27904561-BDEE-47F8-9746-C9CADDD0C2C1

P31

Q38208461-C3D5564D-580F-4FE2-B137-2E4FFAC4AC67

P356

Q38208461-7C7B0308-BDD4-48FD-9B78-0D7BFD05A9D2

P407

Q38208461-3B6F1DB8-E7F6-493A-8F4C-FE457A662B49

P433

Q38208461-04534A98-B4B8-44DF-889C-6FBD94B4ABF0

P478

Q38208461-311EE243-92CF-4E61-8BAD-A7BC96A1F44A

P577

Q38208461-E4B9CF5A-8917-40C7-AE2D-48F619CBE271

P698

Q38208461-A9581FFA-2471-4C03-8624-DB13B4E6FC74

P921

Q38208461-1F0649B1-EC6A-4B0B-A5DF-3D37CE5B5101

P356

17425255.2014.915028

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Pharmacokinetic and pharmacody ...... atment of Alzheimer's disease.

@en

P2093

Barbara Schneider

http://www.w3.org/2001/XMLSchema#string

David Prvulovic

http://www.w3.org/2001/XMLSchema#string

P2860

Global prevalence of dementia: a Delphi consensus study

Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2

The sigma receptor: evolution of the concept in neuropsychopharmacology

Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival

The cholinergic hypothesis of geriatric memory dysfunction

Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers

Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy

Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study.

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.

P304

1039-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2014.915028

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24785550

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease